Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease

• Published in: Journal of gastroenterology Vol. 54; no. 8; pp. 718 - 729
• Main Authors: Miwa, Hiroto, Igarashi, Ataru, Teng, Lida, Uda, Akihito, Deguchi, Hisato, Tango, Toshiro
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.08.2019; Springer; Springer Nature B.V
• Subjects: Abdominal Surgery; Bayesian analysis; Clinical trials; Colorectal Surgery; Drug therapy; Gastroenterology; Gastroesophageal reflux; Hepatology; Medicine; Medicine & Public Health; Meta-analysis; Omeprazole; Original Article—Alimentary Tract; Original —Alimentary Tract; Proton pump inhibitors; Remission; Surgical Oncology; Systematic review; Network meta-analysis; Potassium-competitive acid blocker; Vonoprazan; Gastroesophageal reflux disease; Proton-pump inhibitor
• ISSN: 0944-1174; 1435-5922
• DOI: 10.1007/s00535-019-01572-y

Background Long-term maintenance treatment of gastroesophageal reflux disease (GERD) is important to prevent relapse. Proton-pump inhibitors (PPIs) are used for both treatment and maintenance therapy of GERD. Recently, a potassium-competitive acid blocker vonoprazan was launched in Japan. We evaluated the comparative efficacy of vonoprazan and other PPIs for GERD maintenance. Methods A systematic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials. Double-blind randomized controlled trials (RCTs) of PPIs, vonoprazan, and placebo for GERD maintenance published in English or Japanese were selected. Among them, studies conducted at the recommended dose and for the recommended use, and containing information on maintenance rate based on endoscopic assessment, were included. The comparative efficacies of treatments were estimated by performing a Bayesian network meta-analysis, which assessed the consistency assumption. Outcomes were number or rate of patients who maintained remission. Results Of 4001 articles identified, 22 RCTs were eligible for analysis. One study published as an abstract was hand-searched and added. The consistency hypothesis was not rejected for the analysis. The odds ratio of vonoprazan 10 mg to each PPI was 13.92 (95% credible interval [CI] 1.70–114.21) to esomeprazole 10 mg; 5.75 (95% CI 0.59–51.57) to rabeprazole 10 mg; 3.74 (95% CI 0.70–19.99) to lansoprazole 15 mg; and 9.23 (95% CI 1.17–68.72) to omeprazole 10 mg. Conclusions The efficacy of vonoprazan in GERD maintenance treatment may be higher than that of some PPIs. However, a direct comparison of vonoprazan and PPIs is required to confirm these effects.